We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

By LabMedica International staff writers
Posted on 16 Jan 2025

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the width of five human hairs. More...

The tool, called MISO (Multi-modal Spatial Omics), processes vast amounts of data and applies insights to even the smallest regions on medical images. It has the potential to guide doctors toward the most effective therapies for various cancers, according to a recent paper about MISO published in Nature Methods.

MISO was developed by researchers at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA) to work in the field of "spatial multi-omics." This area of research aims to gain insights into different conditions by considering the physical arrangement of tissue while examining various "-omics" modalities, such as transcriptomics (gene expression), proteomics (proteins), and metabolomics (metabolites and their processes), among others. In spatial transcriptomics, for example, a single pixel in an image contains 20,000 to 30,000 data points that need to be analyzed across multiple -omics layers, and this number can increase significantly if multiple omic layers are considered. By comparison, MRI and CT scans have only one data point (shades of gray) per pixel to interpret. Without AI tools like MISO, doctors and researchers would find it nearly impossible to uncover the valuable insights that the system can detect.

Using MISO, the researchers uncovered new information about several types of cancer, including bladder, gastric, and colorectal cancers, by analyzing data and images from donated patient tissue. In bladder cancer, MISO identified a specific group of cells responsible for forming tertiary lymphoid structures, which are associated with better responses to immunotherapy. In gastric cancer, MISO was able to differentiate cancer cells from the surrounding mucosa. In colorectal cancer, the system identified various sub-classes of cancer cells, shedding light on the distinct malignant cells within a single tumor. MISO was also used to analyze non-cancerous brain tissue structures.

These breakthroughs can guide more effective therapies, improve survival rates, and provide insights that are very challenging, if not impossible, to obtain without an advanced AI tool like MISO. Moving forward, the team aims to expand their knowledge of spatial -omics and pathology imaging to enhance MISO’s capabilities, including the ability to analyze multiple tissue samples simultaneously, which would greatly increase its output. While some data, such as epigenetic marks (chemicals that regulate DNA and are influenced by the environment), have not yet been widely measured, MISO’s AI system allows it to "learn" from the information it processes, enabling it to recognize new data as it becomes more available.

“As the field of spatial omics advances, it has become possible to measure multiple -omics modalities from the same tissue slice, providing complementary information and offering a more comprehensive, insightful view,” said Mingyao Li, PhD, the study’s senior author and a professor of Biostatistics and Digital Pathology. “MISO addresses a huge data challenge by enabling simultaneous analysis of all spatial -omics modalities, as well as microscopic anatomy images when available. It is the only method that is able to handle datasets like these with hundreds of thousands of cells per sample.”

Related Links:
Perelman School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Slide Scanner System
NanoZoomer S540MD
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.